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The vascular endothelial growth factor (VEGF)/VEGF recep-
tor 2 (VEGFR-2) pathway regulates proliferation, survival,
and permeability of vasculature. This pathway is active dur-
ing the formation of a corpus luteum, a highly vascularized,
endocrine organ with a short life span during the nonpreg-
nant state. In the pregnant state, the life span of corpora lutea
is much longer because they play a critical role in supporting
pregnancy development. We hypothesized that the VEGF/
VEGFR-2 pathway plays a critical role in regulating angio-
genic events in the corpora lutea of pregnancy. Injection of the
neutralizing anti-VEGFR-2 antibody DC101 (ImClone Sys-
tems, Inc., New York, NY) on embryonic d 3.5 (preimplanta-
tion) or 6.5 (postimplantation) disrupts function of the cor-
pora lutea of pregnancy in CD1 mice, as evidenced by a
decrease in organ size, regression of luteal vessels, and a fall
in progesterone secretion within 24 h postinjection. Inhibi-
tion of the VEGFR-2 caused removal of endothelial cells,
mostly through endothelial cell detachment from the vascular
basement membrane. Luteal steroid-producing epithelial
cells were eliminated through apoptosis secondary to vascu-
lature becoming dysfunctional. Disruption of luteal function
caused arrest of embryonic development. The effect of anti-
body is specific to the ovary, because pregnancy progresses
normally in ovariectomized, progesterone-replaced animals
treated with anti-VEGFR-2 antibody. Embryonic blood ves-
sels were not affected directly by the antibody, because it did
not reach the embryo. Administration of an antibody against
VE-cadherin (E4G10), which specifically blocks endothelial
proliferation, did not disrupt luteal function and pregnancy
development. Thus, VEGFR-2-mediated endothelial cell sig-
nals are critical to maintain functionality of luteal blood ves-
sels during pregnancy. Potential clinical applications of in-
hibitors of the VEGF/VEGFR-2 pathway include emergency
contraception and medical treatment of ectopic and abnormal
intrauterine pregnancies. (Endocrinology 146: 1301–1311,
2005)
THE CORPUS LUTEUM is a temporary, endocrine struc-ture with a short life span in the nonpregnant state. It
is formed from a preovulatory follicle, whose hallmark is a
centrally located, fluid-filled cavity. After ovulation this cav-
ity fills rapidly with epithelial and endothelial cells through
proliferative events transforming it into a solid structure.
Epithelial cells are derived from granulosa and thecal cells,
whereas endothelial cells originate from preexisting, thecal
layer blood vessels. The corpus luteum is a highly vascular-
ized organ whose vascular density exceeds those of most
tumors. Once formed, the vasculature is maintained for a
limited period of time in the nonpregnant state. When a new
estrous or menstrual cycle is initiated, the corpus luteum
regresses as luteal epithelial and endothelial cells are elim-
inated (1, 2). This is in contrast to the pregnant state, where
the presence of blood vessels in corpora lutea is required for
a longer period of time to maintain functionality throughout
at least part, if not the entire, pregnancy. Because luteal
proliferative events are very few in the early stages of preg-
nancy, at least in rodents, maintenance of function occurs
mostly through securing the survival of epithelial and en-
dothelial cells (3).
One important pathway regulating angiogenic events is
VEGF acting through two receptors: VEGF receptor 1
(VEGFR-1) and VEGFR-2 (4). Alternative exon splicing re-
sults in the formation of four different isoforms with 121, 165,
189, and 206 amino acid forms, respectively (murine VEGF
is shorter by one amino acid), with VEGF165 being the pre-
dominant one. It is thought that VEGF-dependent activation
of VEGFR-2 is involved in mediating endothelial cell pro-
liferation, survival, and vascular permeability, whereas
VEGFR-1 might play an inhibitory role by sequestering
VEGF, and thus preventing its interaction with VEGFR-2 (4).
Regulation of angiogenic events in corpora lutea is only
partially understood. The VEGF/VEGFR-2 pathway is active
in angiogenesis, occurring during the formation of corpora
lutea, as evidenced by the fact that substances inactivating
VEGF or the VEGFR-2 interfere with luteal blood vessel
proliferation (5–7). It is not clear whether this angiogenic
pathway is also active in regulating endothelial function in
corpora lutea of pregnancy. For example, in rodents, admin-
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istration of anti-VEGF antibody seems to interfere with early
pregnancy development by affecting predominantly endo-
thelial proliferative events in the uterus, whereas effects on
ovarian function seem to be less pronounced (8, 9). In con-
trast, administration of anti-VEGF antibody to pregnant rats,
which were hypophysectomized and hysterectomized,
seems to counteract estradiol-dependent rescue of luteal
function by decreasing progesterone (P4) levels and slightly
diminishing luteal vascular density (10), indicating that lu-
teal function is dependent on VEGF. Observations made in
mouse tumor models are relevant in this context, because
they suggest that anti-VEGF antibodies not only inhibit an-
giogenesis, but also induce regression of preexisting blood
vessels, suggesting a regulatory role in endothelial survival
(11–13). Based on VEGF-related findings in nonpregnant and
pregnant corpora lutea as well as in tumors, we hypothesized
that the VEGF/VEGFR-2 pathway plays a critical role in
the regulation of angiogenic events in corpora lutea of
pregnancy.
We report that a single pre- or early postimplantation
administration of anti-VEGFR-2 antibody (DC101, ImClone
Systems, New York, NY) in pregnant CD1 mice disrupts
survival of preexisting luteal blood vessels in the ovary and
terminates embryonic development through its effects on
ovarian hormone production. Inhibitors of the VEGF/
VEGFR-2 pathway, therefore, may be helpful in the devel-
opment of new types of contraceptives and in the treatment
of pathological conditions such as ectopic pregnancy.
Materials and Methods
Behavior of the antibody DC101 in vivo in
pregnant animals
Access of maternal substances to embryonic structures is selective
due to protective barriers (zona pellucida, trophoblast, and placenta
with chorion) surrounding the embryo and fetus. Thus, we first studied
the binding pattern of the rat monoclonal anti-VEGFR-2-blocking anti-
body DC101 (ImClone Systems, Inc.) after administration to pregnant
mice to determine whether it can affect maternal and embryonic tissues
simultaneously during pregnancy. Animals were injected with saline
(control; n  2) or increasing dosages of DC101 (66, 132, and 264 mg/kg;
n  2/group) on embryonic d (ED) 6.5 or 12.5, and killed on ED 7.5 or
13.5. A dosage of 66 mg/kg animal inhibits ovarian angiogenesis (14).
Ovary, uterus containing the embryo, liver, and kidney were removed
for characterization of DC101 localization. Frozen tissue sections of these
organs from control and anti-VEGFR-2 antibody-treated animals were
incubated with mouse absorbed, affinity-purified, biotinylated rabbit
antirat IgG secondary antibody (Vector Laboratories, Inc., Burlington,
CA). This immunohistochemical approach allowed identification of tis-
sues to which the blocking antibody DC101 was bound. No staining for
anti-VEGFR-2 antibody was detected in any of the control group tissue
sections. Binding of DC101 to vascular structures in the ovary, uterus,
liver, and kidney was consistently detected with the secondary antibody
in treatment group animals. In contrast, no DC101 binding to embryonic
structures, including vasculature, was detected with the secondary an-
tibody. To test whether DC101 has the ability to bind to embryonic
vascular structures, we incubated slides onto which tissue cross-sections
of uterus and embryonic tissue from pregnant control animals were
mounted, with the blocking antibody DC101 as the primary antibody.
Under these conditions, the secondary antibody detected embryonic
vascular (ED 13.5) structures through its binding to DC101. We con-
cluded that antibody injected into pregnant animals binds to maternal
blood vessels, including ovary and uterus, but does not reach embryonic
structures.
Experiment 1: effect of the anti-VEGFR-2 antibody DC101
on ovarian function and pregnancy development
Seven animals per group were used in all experiments. Implantation
occurred on ED 4.5.
Experiment 1a: postimplantation (ED 6.5)
Three-month-old female CD1 mice (Charles River Laboratories, Bal-
timore, MD) were mated with males of proven fertility overnight. Iden-
tification of a vaginal plug the following morning was interpreted as
successful mating and counted as d 0.5 of pregnancy. Plugged female
mice were randomized into two groups. Control group animals received
a single ip injection of saline (0.5 ml) on ED 6.5. Treatment group animals
received a single ip injection of anti-VEGFR-2 antibody (66 mg/kg;
DC101, ImClone Systems, Inc.) on ED 6.5. Such a dose is sufficient to
inhibit angiogenesis in corpora lutea (7). Animals were killed on ED 7.5,
and 13.5. A baseline group of animals were also killed on ED 6.5 to serve
as a reference for the evaluation of ovaries. Uterus, both ovaries, one
kidney, and part of the liver were removed from all animals for histo-
logical and/or immunohistochemical/immunofluorescent evaluation.
Experiment 1b: preimplantation (ED 3.5)
Plugged female mice were randomized to two groups. Control group
animals received a single ip injection of saline (0.5 ml) on ED 3.5. Treatment
group animals received a single ip injection of anti-VEGFR-2 antibody (66
mg/kg; DC101) on ED 3.5. Animals were killed on ED 4.5, 7.5, and 13.5. A
baseline group of animals was also killed on ED 3.5 to serve as a reference
for the evaluation of ovaries. Uterus, both ovaries, one kidney and part of
the liver were removed from all animals for histological and/or immuno-
histochemical/immunofluorescent evaluation.
Experiment 2: effect of anti-VEGFR-2 antibody DC101
on pregnancy development in ovariectomized,
hormone-replaced animals
Substances originating from the products of conception could play an
important role in the maintenance of luteal vasculature (15). If so,
DC101-induced changes in luteal vasculature could have been indirect,
through disruption of pregnancy development by interfering with the
function of decidual tissue. We tested for such a possibility by following
pregnancy development in ovariectomized, P4-replaced animals ex-
posed to DC101 before or after implantation. Pregnancy in such animals
can be maintained by exogenously administered P4 (16). Five animals
were used in each group.
Experiment 2a: postimplantation (ED 6.5)
Four 10-mg 21-d release P4 capsules (Innovative Research of America,
Sarasota, FL) were placed sc on the left and right sides (two capsules per
side) of the neck of pregnant female mice on ED 5.5 using a small trocar
provided by the company for this purpose. Ovariectomy was performed
in all animals on ED 6.0. Hormone-replaced, ovariectomized animals
were then randomized into the control group, which received a single
ip injection of saline (0.5 ml) on ED 6.5, and the treatment group, which
received an injection of a single dose of anti-VEGFR-2 antibody (66
mg/kg; DC101) on ED 6.5. Animals were killed on ED 7.5 and 13.5. Uteri
were removed from all animals for histological and/or immunohisto-
chemical evaluation.
Experiment 2b: preimplantation (ED 3.5)
P4 capsules (Innovative Research of America) were placed sc in
plugged female mice on ED 2.5. Ovariectomy was performed in all
animals on ED 3.0. Hormone-replaced, ovariectomized animals were
then randomized into a control group, which received a single ip in-
jection of saline (0.5 ml) on ED 3.5, and a treatment group, which
received an injection of a single dose of anti-VEGFR-2 antibody (66
mg/kg; DC101) on ED 3.5. Animals were killed on ED 13.5. Uteri were
removed for histological evaluation.
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Experiment 3: effect of anti-VE-cadherin antibody
E4G10 administered on ED 6.5 on ovarian function
during pregnancy
To determine whether the proliferation of endothelial cells occurs in
corpora lutea of pregnancy, we evaluated the effect of the anti-VE
cadherin antibody E4G10 (ImClone Systems, Inc.) (17). This antibody
specifically blocks angiogenesis, but does not affect blood vessel sur-
vival. Plugged female mice were randomized to two groups. Control
group animals received a single ip injection of saline (0.5 ml) on ED 6.5.
Treatment group animals received a single ip injection of rat anti-VE
cadherin antibody (264 g/kg; E4G10), which specifically blocks an-
giogenesis, on ED 6.5. Such a dose inhibits angiogenesis during the
formation of corpora lutea (18). Animals (n  3/group and day of death)
were killed on ED 7.5 or 13.5. A baseline group of animals was also killed
on ED 6.5 to serve as a reference for the evaluation of ovaries. The uterus
and both ovaries were removed from all animals for histological and
immunohistochemical evaluation.
Identification of implantation sites and evaluation of ovary,
uterus, and pregnancy by histology
Each completely dissected uterus containing the embryos was
weighed, and the number of implantation sites per animal was counted
by visual inspection. Subsequently, one ovary and approximately half
of the uterus containing the embryos were immersed in formalin for
fixation, then stored in 70% ethanol. Tissues of interest were embedded
in paraffin, sectioned at 10 m, and stained with hematoxylin and eosin
(H&E) according to standard histological protocols. To select a corpus
luteum suitable for evaluation, 20–30 slides of each ovary were evalu-
ated, the corpus luteum with the largest diameter was identified, and its
diameter was measured.
Immunohistochemistry/immunofluorescence
The contralateral ovary, the remaining uterus, one kidney (experi-
ment 1), and part of the liver (experiment 1) were embedded in OCT
(Miles, Inc., Elkhart, IN), snap-frozen in dry ice-cooled isopentane, and
stored at 80 C degrees. Frozen ovaries were sectioned at 5-m inter-
vals. Thirty sections were obtained, and every fifth slide was stained
with H&E. One to 30 slides were evaluated. The slide containing the
largest cross-section through a corpus luteum was identified and given
the number 0. The sections preceding (identified by ) and after (iden-
tified by ) this H&E section were selected for immunohistochemical/
immunofluorescent evaluation.
Endothelial cells (1). Section 1 was evaluated for the presence of blood
vessels in corpora lutea using an antibody against platelet endothelial
cell adhesion molecule (PECAM; biotin-conjugated rat antimouse CD 31
monoclonal antibody, 1:200; BD Pharmingen, San Diego, CA) (19, 20)
following standard immunohistochemical procedures (7). It is possible
that anti-VEGFR-2 antibody influences the expression of PECAM on
endothelial cells. We theorized that if the expression pattern of PECAM
correlated closely with the expression pattern of a second angiogenic
marker, such a possibility would be less likely. Therefore, in a pilot
experiment we incubated two consecutive ovarian sections from three
control and treatment group pregnant animals (ED 7.5 and 13.5)
with antibody against PECAM and antibody against VE-cadherin
RDI-MCD144-11D4 (rat antimouse monoclonal antibody, 1:20; Research
Diagnostics, Flanders, NJ) following the manufacturer’s instructions
(18). Because the patterns of staining for PECAM and VE-cadherin
nearly completely overlapped in all sections, we conclude that treatment
with anti-VEGFR-2 antibody did not significantly affect the expression
of PECAM. Only staining for PECAM is shown in this report, because
it is more robust.
Nuclear cell number (2). Section 2 was stained with hematoxylin to
identify nuclei of individual cells.
Apoptosis (3 and 4). Apoptotic cells were detected using rabbit an-
tihuman/mouse caspase 3 antibody (rabbit antimouse antibody, 1:500;
R&D Systems, Inc., Minneapolis, MN) following the manufacturer’s
instructions (21). Because antibody against caspase 3 might detect both
active and inactive proteins, we evaluated the presence or absence of
apoptosis with a second marker by staining for DNA fragmentation
using the ApopTag kit (Intergen, Purchase, NY) following the manu-
facturer’s instructions (14). Quantitative evaluation revealed a close
correlation between the two methods (0.82), with the number of cells
staining positively for caspase 3 being lower compared with staining
with the ApopTag kit. Results with the ApopTag kit are shown because
the staining was more robust than caspase staining.
Cell proliferation (5). Animals were injected 1 h before death with
5-bromo-2-deoxyuridine (BrdU; 1 ml/100 g animal weight; Zymed
Laboratories, Inc., San Francisco, CA). Proliferating cells were identified
with a biotinylated mouse anti-BrdU primary antibody (Zymed kit)
following the manufacturer’s instruction (14).
Pericytes (6). Pericytes were detected using monoclonal anti--smooth
muscle actin antibody (antimouse monoclonal antibody, 1:500; Sigma-
Aldrich Corp., St. Louis, MO) together with the mouse on mouse kit
(Vector Laboratories, Inc., Burlingame, CA) following the manufactur-
er’s instructions.
Sections 1 to 4 were incubated with PECAM in combination with
another primary antibody, and immunofluorescence was used for an-
tibody detection. Immunofluorescent staining was performed by incu-
bating sections with biotinylated primary antibodies, then the signals
were detected using fluorescent dye conjugate of streptavidin, Alex-
aFluor 488 (1:200; green) and AlexaFluor 594 (1:200; red; Molecular
Probes, Inc., Eugene, OR), applied for double labeling following the
manufacturer’s instructions (14). Nonbiotinylated primary antibodies
were first incubated with a biotinylated secondary antibody, and signal
detection was performed as described above.
Basement membrane (1). Basement membrane was identified with an
antibody against collagen IV (rabbit polyclonal antibody, 1:7000; Cosmo
Bio Co. Ltd., Tokyo, Japan), a constituent of the vascular basement
membrane, following the manufacturer’s instructions (22). This allowed
for detection of vascular basement membrane surrounding endothelial
cells (22).
The non-PECAM antibody used in section 2 was against caspase 3,
ApopTag was used in section 3, and an antibody against BrdU was
used in section 4. This approach allowed us to detect apoptotic and
proliferative endothelial and epithelial cells in corpora luteal of
pregnancy.
Controls. Negative controls from control and treatment groups (ovary,
uterus, kidney, and liver) were included in all immunohistochemical
and immunofluorescent tissue evaluations. To obtain such negative
controls, the primary antibody was omitted, but otherwise the proce-
dural steps were the same as those described above. No significant
nonspecific staining was observed in any of the tissue samples analyzed
in the absence of primary antibody; therefore, data are not shown.
Serum P4
Blood was obtained from all animals by cardiopuncture at the time
of death. Serum P4 levels were measured using a ligand-labeled, com-
petitive, chemiluminescent immunoassay (Diagnostic Products Corp.,
Los Angeles, CA) (14).
Data analysis
Quantitative analysis of endothelial cells (PECAM), proliferation
(BrdU), and apoptosis (caspase 3 and DNA fragmentation) was per-
formed using an image analysis system linked to an Eclipse E800 camera
(Nikon, Melville, NY). The data were processed for quantitative analysis
using ImagePro Plus version 4.01 (Silver Spring, MD). For corpora lutea
and uterine sections, this analysis was performed as follows.
Blood vessel density (BVD). The area of interest in a cross-section was
outlined, highlighted, and measured in square millimeters. Subse-
quently, specifically stained tissue (brown staining for PECAM in im-
munohistochemical sections) in the same area was highlighted and
measured in square millimeters. Then the density of specific staining, e.g.
PECAM staining for vasculature, was calculated by forming the ratio of
the area of specific staining divided by the total area of the structure of
interest (corpus luteum) multiplied by 100. In uterine cross-sections, the
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decidual area was outlined, and BVD was evaluated as described for
corpora lutea.
Proliferation and apoptosis. The total area of a cross-section was outlined.
The image analysis system was set up to measure the number of dark-
stained nuclei or cells (BrdU and apoptosis) using the segmentation part
of the computer program. An adjacent section, which was stained with
hematoxylin, allowed for counting the total number of luteal cells iden-
tified as blue-stained nuclei. A proliferation index was formed (i.e. BrdU-
positive cells, expressed as a percentage of the total number of luteal
cells). For apoptosis, the values obtained in the postimplantation group
on ED 6.5 (baseline) and in the preimplantation group on ED 3.5 (base-
line) were set at 100%, and the deviations seen on ED 4.5, 7.5, or 13.5 were
calculated as the percent change from baseline.
Statistical analysis
Data are presented as the mean  se. ANOVA and unpaired t test
were used, with a significance level set at P  0.05. Microsoft Excel was
used to perform the above statistical tests.
Animals were observed for signs of distress, such as decreased food
or water intake, decreased activity, abnormal posture or gait, abnormal
behavior or vocalization, and increase in lethargy, for 2 h after the
injection of the antibody and for 1 h daily thereafter until death. No
systemic side-effects of antibody DC101 were observed in any of the
mice.
All experiments were conducted in accordance with the principles
and procedures of the NIH Guide for the Care and Use of Laboratory
Animals and had been approved by the Columbia University institu-
tional animal care and use committee.
Results
Effect of a single post- or preimplantation injection of
anti-VEGFR-2 antibody DC101 on ovarian function and
pregnancy development
Postimplantation (injection of anti-VEGFR-2 antibody DC101 on
ED 6.5). The diameter of control group corpora lutea re-
mained unchanged in postimplantation pregnancy. In con-
trast, luteal size decreased significantly by 24 h after antibody
administration in treatment group animals (30% decline
compared with controls) and reached its nadir on ED 13.5
(Fig. 1A and Table 1A), indicating that due to the action of
anti-VEGFR-2 antibody DC101, treatment group corpora
lutea function must have been compromised. Such dysfunc-
tion of treatment group corpora lutea was reflected by the
fact that a significant decline in ovarian P4 secretion oc-
curred, starting 24 h after antibody administration, com-
pared with controls (Fig. 2A). Evaluation at the cellular level
revealed that in the treatment group luteal BVD had de-
creased significantly 1 d after antibody administration (ED
7.5; Fig. 1B), and was maintained at this level as pregnancy
progressed (Table 1A). In contrast, BVD in control group
corpora lutea remained unchanged as pregnancy advanced
to ED 13.5 (Fig. 1B and Table 1A). Qualitative evaluation of
luteal blood vessels demonstrated that they stained posi-
tively for PECAM, but were mostly negative for -smooth
muscle actin, a marker for pericytes (Fig. 1C). The absence of
pericytes is considered a hallmark of immature microvas-
culature, indicating increased vulnerability when depriva-
tion of VEGF action occurs (20). Subsequently, we examined
possible mechanisms of cell elimination in corpora lutea.
Although apoptosis was very low throughout pregnancy in
control group corpora lutea (Fig. 1D), it increased signifi-
cantly 24 h after antibody administration (Fig. 1D) and re-
mained above the control value with the continuation of
pregnancy (Table 1A). Immunofluorescent double staining
for apoptosis and PECAM demonstrated that apoptotic ep-
ithelial cells dominated over apoptotic endothelial cells in
treatment group corpora lutea (Fig. 3B). The apoptotic ratio
of epithelial to endothelial cells was approximately 15:1
throughout pregnancy. Apoptosis and endothelial cell re-
gression were rarely seen in treatment group corpora lutea
before 24 h after antibody administration (our unpublished
observation), indicating that a time period of approximately
24 h was necessary to obtain significant treatment effects.
Based on these observations, it can be concluded that one
mechanism of epithelial cell elimination is apoptosis,
whereas nonapoptotic mechanisms seem to be more impor-
tant for luteal endothelial cell elimination. One possibility is
that endothelial cells could have become detached from base-
ment membranes, leaving vascular basement membrane
ghosts behind as dysfunctional blood vessel residua (2, 20).
Such ghosts would be a historical record of previously ex-
isting blood vessels, which have become dysfunctional (20).
Double staining with antibodies against collagen IV, a vas-
cular basement membrane component (20), and PECAM, an
FIG. 1. Cross-section through the corpora lutea of pregnancy evalu-
ated on ED 7.5 from animals injected with saline (control; left column)
or DC101 (treatment; right column) on ED 6.5 using serial sections.
A, H&E staining of corpora lutea; note the decreased size of treatment
corpus luteum. B, PECAM staining shown in brown; note the decrease
in vascular density in the treatment group. C, -Smooth muscle actin
staining; note the absence of staining inside control and treatment
group corpora lutea. D, Apoptosis (ApopTag) staining shown in brown;
note an increase in staining in the treatment group.
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endothelial cell marker (19), revealed that in treatment group
corpora lutea, many basement membranes were devoid of
endothelial cells (collagen IV-only structures or basement
membrane ghosts; Fig. 4, treatment groups A–C). In contrast,
most of the basement membranes in controls colocalized
with endothelial cells (collagen IV staining associated with
PECAM staining; Fig. 4, control groups A–C). These findings
indicate that the endothelial cells must have regressed
through the action of anti-VEGFR-2 antibody DC101, possi-
bly through detachment from the basement membrane, mak-
ing these remnant vessels dysfunctional. Cell proliferation
was noncontributory to the observed phenomena, because it
was very low in control and treatment group corpora lutea
throughout pregnancy [0.2–0.3% of all cells per corpus lu-
teum; not significant (n.s.); Fig. 3A]. The above data also seem
to indicate that no recovery of luteal function through new
epithelial and endothelial cell division occurred, because no
increase in luteal size or vascular density was seen on ED 13.5
in the treatment group, even though the effects of antibody
injection are short term (23).
The biological significance of these ovarian antibody ef-
fects was assessed by examining pregnancy development.
Uterine weight increased significantly in the control group as
pregnancy progressed (0.43  0.06 g on ED 7.5 to 6.89  0.73 g
on ED 13.5), reflecting appropriate growth of the uteri and
progression of embryonic development (Table 1B). The num-
ber of implantation sites (on the average, 13) did not change
significantly over time (Table 1B). Uterine weights in treat-
ment group animals were similar to those in control group
FIG. 2. Maternal P4 levels. A, Postimplantation experiment. The
control group (blue line) was injected with saline on ED 6.5; the
treatment group (red line) was injected with DC10 on ED 6.5. B,
Preimplantation experiment. The control group (blue line) was in-
jected with saline on ED 3.5; the treatment group (red line) was
injected with DC10 on ED 3.5. Asterisks indicate a statistically sig-
nificant difference.
FIG. 3. Immunofluorescence staining for proliferation and PECAM
(A) and apoptosis and PECAM (B) of control and treatment group
corpora lutea from an animal injected with saline (control; left col-
umn) or DC101 (treatment; right column) on ED 6.5 and evaluated on
ED 7.5. Proliferation (A): green, blood vessels stained for PECAM; red,
proliferative cells. Please note low proliferation in control and treat-
ment. On lower right in treatment proliferative cells of a follicle.
Apoptosis (B): green, blood vessels stained for PECAM; red, apoptotic
cells. Please note nearly complete absence of apoptosis in control; note
presence of apoptotic cells without simultaneous staining for PECAM
(epithelial cells; b) in treatment; also note few cells stained yellow
representing apoptotic endothelial cells (a).
TABLE 1. Effects of postimplantation administration of DC101 (ED 6.5) on ovary, uterus, and pregnancy
A. Diameter, vascular density, and apoptosis in control and treatment group corpora lutea
ED
Diameter (mm) Vascular density (%) Apoptosis (%)
Control Treatment P Control Treatment P Control Treatment P
6.5 0.63  0.05 100 (baseline) 100 (baseline)
7.5 0.61  0.08 0.45  0.05 0.02 101  1.9 32  3.9 0.01 102  4.1 568  12.4 0.01
13.5 0.65  0.04 0.39  0.04 0.01 112  4.5 39  2.4 0.01 99  5.4 184  6.5 0.05
B. Uterine weight and implantation sites in control and treatment group corpora lutea
ED
Uterine weight Implantation sites
Control (g) Treatment (g) P Control Treatment P
6.5 0.38  0.05 13.1  1.3
7.5 0.43  0.06 0.41  0.08 n.s. 13.5  0.9 13.1  0.7 n.s.
13.5 6.89  0.73 0.25  0.11 0.01 13.0  1.1 0 0.01
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animals on ED 7.5 (0.4 g; Table 1B), but were significantly
decreased on ED 13.5 (0.25  0.11 g; Table 1B). In treatment
group animals, the number of implantation sites was similar
to that in controls on ED 7.5; however, on ED 13.5, no im-
plantation sites were seen (Fig. 5A and Table 1B). Histolog-
ically, serial sections of control group uteri on ED 7.5 and ED
13.5 (Fig. 5B) revealed normal development corresponding to
gestational age. Treatment group embryos appeared similar
to controls on ED 7.5. However, there was a complete absence
of embryonic structures and placentas by pregnancy d 13.5
(Fig. 5B and Table 1B).
Preimplantation (injection of anti-VEGFR-2 antibody DC101 on
ED 3.5). Similar to the postimplantation experiment, the size
of treatment group corpora lutea decreased 24 h after anti-
body administration and reached its nadir on ED 7.5 (Table
2A). Due to effects of the antibody injection on ED 3.5, luteal
BVD had decreased significantly on ED 4.5 and was not able
to recover (Table 2A). In the treatment group, apoptosis
(mostly epithelial cells) increased significantly 24 h after
antibody administration compared with controls, and no
additional change was seen with continuation of pregnancy
(Table 2A). Cell proliferation was rarely observed in corpora
lutea in the treatment and control groups (0.2–0.3%; n.s.).
Abnormal function of treatment group corpora lutea was
also reflected by a significant decline in P4 secretion starting
24 h after antibody administration and reaching a nadir on
ED 7.5 (Fig. 2B).
Similar to the postimplantation experiment, the biological
significance of the ovarian effects of antibody were evaluated
by observing pregnancy development. Uterine weights in
treatment group animals increased up to ED 7.5 similar to
control values (Table 2B), but decreased to nonpregnant lev-
els on ED 13.5 (0.20  0.04 g; Table 2B). In treatment group
animals, the number of implantation sites was similar to that
FIG. 4. Immunofluorescent double
staining for vascular basement mem-
brane protein collagen IV and endothe-
lial cell marker PECAM from animals
injected with saline (control; left col-
umn) or anti-VEGFR-2 antibody DC101
(treatment; right column) on ED 6.5
and killed on ED 7.5. A, Staining of en-
dothelial cells in green for PECAM.
Note the decrease in staining in the
treatment group. B, Staining for colla-
gen IV in red. Note that the density of
staining is similar in treatment and
control groups. C, Staining for PECAM
and collagen VI. Note in controls signif-
icant colocalization of PECAM (green)
with collagen IV (red), indicating that
most endothelial cells are surrounded
by vascular basement membrane. In
the treatment group, many vascular
basement membranes are devoid of en-
dothelial cells.
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in controls on ED 4.5; however, on ED 7.5 the sites were less
pronounced compared with controls, and on ED 13.5 no
implantation sites were seen (Table 2B). Histologically, serial
sections through control group uteri on ED 4.5, 7.5, and 13.5
revealed normal development corresponding to gestational
age. Treatment group animals looked similar to controls on
ED 4.5; however, no clear-cut embryonic structures were
seen on ED 7.5, and complete absence of embryonic struc-
tures and placenta was observed on pregnancy d 13.5.
Effect of a single post- or preimplantation injection of
DC101 on pregnancy development in ovariectomized,
P4-replaced animals
Postimplantation (injection of anti-VEGFR-2 antibody DC101 on
ED 6.5). Maternal serum P4 concentrations in ovariecto-
mized, hormone-replaced mice on ED 13.5 were similar to
those in intact pregnant animals with normal ovarian func-
tion (30.97  10.45 vs. 27.00  4.15 ng/ml; n.s.) (15). Uterine
weights (control, 6.89  1.90 g; treatment, 6.72  1.92 g; n.s.)
and the number of implantation sites on ED 13.5 (13 im-
plantation sites/uterus; n.s.; Fig. 6A) were similar in ovari-
ectomized, hormone-replaced control and treatment group
animals. Histologically, serial sections through areas con-
taining placenta and embryos on ED 13.5 in both groups
revealed normal development structures corresponding to
gestational age (Fig. 6B). Therefore, postimplantation de-
cidual function must not have been affected significantly
by DC101, because normal progression of pregnancy in
hormone-substituted, ovariectomized animals was ob-
served in the treatment group. Evaluation of vasculature
(PECAM staining) in decidua surrounding the embryo in
ED 7.5 animals revealed no difference in BVD between
control and treatment groups (34.5  1.2% vs. 35  1.9%;
n.s.; Fig. 7B). To verify that the anti-VEGFR-2 antibody
does not affect uterine function, we repeated the experi-
ment using the same experimental design (n  3), but a
higher dosage of DC101 (132 mg/kg). Results were very
similar to those seen on ED 13.5 using the lower dosage
(data not shown).
Preimplantation (injection of anti-VEGFR-2 antibody DC101
on ED 3.5). Similar to the postimplantation experiments,
maternal serum P4 concentrations in the ovariectomized,
hormone-replaced mice did not differ significantly from
those in pregnant mice with intact ovaries on ED 13.5
(31.70  8.40 vs. 26.1  5.76 ng/ml; n.s.). Uterine weights
(control, 6.71  0.92 g; treatment, 6.47  0.21 g; n.s.) and
number of implantation sites on ED 13.5 (13 implantation
sites/uterus; n.s.) showed no significant difference. Histo-
logically, serial sections through areas containing placenta
and embryos in both groups revealed normal development
structures corresponding to gestational age. Because preg-
nancy progressed normally in hormone-substituted, ovari-
ectomized animals, the functionality of the decidua must not
have been affected significantly by the administration of
anti-VEGFR-2 antibody DC101 before implantation.
Effect of VE-cadherin antibody
Administration of a single dose of VE-cadherin antibody
on ED 6.5 had no effect on pregnancy development. There
was no difference in uterine weight (control, 6.8  0.87 g;
treatment, 7.1  0.95 g; n.s.), number of implantation sites
(13/uterus in control and treatment groups; n.s.), histo-
logical appearance of embryos, or P4 levels (control, 25.6 
1.7 ng/ml; treatment, 25.1  4.1 ng/ml). Also, luteal BVD
was similar (baseline control ED 6.5, 100%; control ED 7.5,
102  3.6%; treatment, 99.2  4.1%; n.s.).
Effects of DC101 on permanent vasculature
Liver and kidney tissue sections from all control and treat-
ment animals were evaluated histologically (H&E) and im-
munohistochemically (PECAM) in experiment 1. No differ-
ence between control and treatment groups was detected
(data not shown).
Discussion
Pre- and postimplantation administration of a single dose
of anti-VEGFR-2 antibody DC101 disrupted maternal ovar-
ian function through elimination of preexisting luteal blood
vessels. As a secondary effect, pregnancy development was
abnormal. In contrast, pregnancy proceeded normally in
ovariectomized, anti-VEGFR-2-treated animals substituted
with P4. Embryonic blood vessel development was not af-
fected directly by the antibody, because it did not reach the
embryo. Therefore, during pregnancy, the activated VEGF/
VEGFR-2 pathway is of critical importance for the survival
and maintenance of luteal vasculature in the ovary.
Corpora lutea of pregnancy are highly vascularized and
have a much longer life span than nonpregnant corpora
lutea. Angiogenesis is very active in the early luteal phase
immediately after ovulation when corpora lutea are being
formed (5). During the early stages of pregnancy, luteal an-
giogenesis is minimal (3) (our data), and preexisting vessels
are maintained in these corpora lutea for at least part of, if
FIG. 5. Comparison of control and treatment group uteri in intact,
pregnant animals injected on ED 6.5 with either saline (control) or
DC101 (treatment) and killed on ED 13.5. A, Gross specimens; note
the small size of the treatment group uterus. B, Cross-section; the
control shows part of the placenta and liver in the developing embryo.
Note the absence of products of conception in the treatment group
uterus on the right.
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not the entire, pregnancy. Corpora lutea function as endo-
crine organs to maintain pregnancy. After systemic admin-
istration of DC101, a blocking antibody directed against
VEGFR-2, in the pre- or early postimplantation period, spe-
cific antibody binding is detected in many of the endothelial
cells of the microvasculature present in pregnant corpora
lutea. As a consequence of the blockage of the VEGF/
VEGFR-2 pathway through binding of DC101 to luteal vas-
culature, endothelial cells are eliminated rapidly, as dem-
onstrated by a decrease in BVD in all corpora lutea of
pregnancy 24 h after antibody administration. Apoptotic en-
dothelial cells are rarely seen before 24 h after antibody
administration, indicating that other mechanisms besides
apoptosis (24) must be involved in the elimination of luteal
blood vessels. Modlich et al. (2) described an alternative
mechanism of endothelial cell regression, which occurs dur-
ing physiological luteolysis. They suggest that endothelial
cells can spontaneously detach from the basement mem-
brane, which makes the vessel dysfunctional and leaves be-
hind a denuded membrane. Our observations of the exis-
tence of multiple denuded membranes without endothelial
cells in treatment corpora lutea suggests that endothelial
detachment might be the principal mechanism through
which the anti-VEGFR-2 antibody removed endothelial cells.
Such a mechanism of action is also seen in tumors treated
with angiogenic inhibitors (22). The vascular basement mem-
brane ghosts can be considered a historical record of previ-
ously existing blood vessels in treatment group corpora lutea
(20). In contrast to endothelial cells, a major mechanism of
elimination of steroid-producing epithelial cells is apoptosis.
Because no binding of DC101 to luteal epithelial cells is
detected, it is likely that elimination of epithelial cells by
apoptosis occurs indirectly due to insufficient oxygen supply
secondary to the reduction in vasculature. It becomes clear
from these findings that elimination of cells in the corpora
FIG. 6. Comparison of control and treatment group uteri in ovariec-
tomized, hormone-replaced, pregnant animals injected with saline or
DC101 on ED 6.5 and killed on ED 13.5. A, Gross specimens; note that
uterine size and number of embryos are similar in control and treat-
ment groups. B, Cross-section; note that the dimensions of organs
such as placenta and developing liver of the embryo are very similar
in control and treatment groups.
FIG. 7. Cross-sections through pregnant uteri from ovariectomized,
hormone-replaced animals injected with saline (C, control) or DC101
(T, treatment) on ED 6.5 and killed on ED 7.5. A, H&E staining. A
centrally located embryo surrounded by decidua can be seen in C and
T. B, The vascular density of blood vessels surrounding the embryo
is similar for C and T groups.
TABLE 2. Effects of preimplantation administration of DC101 (ED 3.5) on ovary, uterus, and pregnancy
A. Diameter, vascular density, and apoptosis in control and treatment group corpora lutea
ED
Diameter (mm) Vascular density (%) Apoptosis (%)
Control Treatment P Control Treatment P Control Treatment P
3.5 0.53  0.05 100 (baseline) 100 (baseline)
4.5 0.61  0.07 0.48  0.07 0.03 104  4.9 37  4.5 0.01 103  5.7 578  10.1 0.01
7.5 0.63  0.08 0.39  0.05 0.03 103  2.3 31  1.1 0.01 108  6.1 353  9.1 0.01
13.5 0.65  0.05 0.38  0.04 0.01 111  6.9 34  3.2 0.01 110  6.3 191  8.3 0.05
B. Uterine weight and implantation sites in control and treatment group corpora lutea
ED
Uterine weight Implantation sites
Control (g) Treatment (g) P Control Treatment P
3.5 0.25  0.06
4.5 0.29  0.08 0.25  0.08 n.s. 13.2  1.0 12.8  0.8 n.s.
7.5 0.41  0.06 0.37  0.11 n.s. 13.1  0.9 13.1  1.0 n.s.
13.5 6.85  0.95 0.20  0.04 0.01 12.9  0.9 0 0.01
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lutea of pregnancy is a very complex phenomenon, and we
cannot rule out that it might also involve forms of cell death
different from conventional apoptosis. As a consequence of
the decreases in blood supply and steroid-producing cells,
pregnant corpora lutea function is severely compromised. As
P4 production and secretion decline, decidual tissue becomes
dysfunctional, and ultimately the uterus, whose function is
dependent on luteal support, can no longer maintain normal
pregnancy development. In agreement with Kashida et al.
(10), who treated pregnant rats with anti-VEGF antibody, we
found that luteal endothelial cell elimination through the
anti-VEGFR-2 antibody was not complete, whereas P4 re-
turned to nonpregnant values. These researchers suggested
that such a constellation indicates that VEGF acting through
VEGFR-2 might also be involved in regulating vascular per-
meability, which influences the release of P4 into the blood-
stream. Ultimately, due to abnormal P4 levels, the products
of conception arrests and embryos are absorbed.
In agreement with previous studies (23), permanent vas-
culature, including microvasculature present in organs such
as kidney and liver, was not affected by the injection of
antibody. Such microvasculature is mature, that is endothe-
lial cells are associated with pericytes, which may make them
more resistant to the effects of antiangiogenic substances. In
contrast, we cannot rule out that high dose, repeated ad-
ministration of antibody might interfere with function of
these organs, because administration of adenovirus-express-
ing and -producing soluble Flt to pregnant rats can cause
damage in these organs 8 d after the injection (25). In contrast
to kidney or liver vasculature, luteal blood vessels found
during pregnancy are immature; that is, endothelial cells are
devoid of pericytes. This anatomical observation might ex-
plain the greater vulnerability of such blood vessels to the
effects of antiangiogenic agents. The survival and mainte-
nance of immature vasculature depend on VEGF, possibly
acting through VEGFR-2 (11, 12, 20). Tumor microvascula-
ture contains a significant number of immature vessels de-
void of pericytes. Survival of such tumor vasculature is se-
verely compromised when the VEGF stimulus is blocked and
tumors start to regress (11, 12, 26). We showed that luteal
function in treatment group animals did not recover after
discontinuation of antibody treatment. This was evidenced
by the fact that no new blood vessels were formed, and
corpora did not increase in size even though the effects of the
antibody are temporary (3 d) (23). Therefore, the persistent
vascular basement membranes devoid of endothelial cells
seen after antibody treatment do not provide a scaffold for
vascular regrowth after cessation of treatment with DC101
(20). Our observation in the rodent is in contrast to findings
in the marmoset. Pregnancies continued to develop normally
after discontinuation of treatment with a VEGF-inactivating
agent, which had been initiated shortly after ovulation, prob-
ably due to renewed luteal angiogenic activity (27). A pos-
sible explanation of this difference is that a short-term de-
crease in P4 can be better tolerated in nonhuman primates,
whose pregnancy lasts much longer than that in rodents. Our
findings might also provide some clues for strategies used to
facilitate rapid tissue regression during luteolysis in rodents
(1). It may be that throughout the luteal phase, blood vessels
are maintained in a vulnerable state dependent on VEGF for
survival. At a particular time point during the life span of a
corpus luteum, when its endocrine function is no longer
required, the local endothelial survival stimulus in the form
of VEGF is withdrawn, and blood vessels become dysfunc-
tional through endothelial cell removal. As a secondary ef-
fect, P4-producing epithelial cells are eliminated, and grad-
ually corpora lutea cease to exist.
The VEGF/VEGFR-2 pathway regulates two very distinct,
biological events pertaining to the vasculature of corpora
lutea: endothelial cell proliferation during the formation of
corpora lutea, and endothelial cell stabilization and survival
during pregnancy to secure its endocrine function. There-
fore, the same VEGF stimulus, through its binding to
VEGFR-2 on endothelial cells, is a proliferative and/or
a survival signal for endothelial cells. Different VEGFR2-
dependent intracellular signaling pathways may be acti-
vated in this situation. Akt is involved in endothelial cell
survival, whereas phospholipase C and MAPK p44/42
stimulate endothelial cell proliferation (28, 29). It is likely
that other angiogenic regulators, such as angiopoietins
acting through Tie 2, also participate in the regulation of
these events (30).
It cannot be ruled out that substances originating from the
products of conception could play a supportive role in the
maintenance of luteal vasculature and function. Adminis-
tration of anti-VEGFR-2 antibody DC101 might have dis-
rupted ovarian function indirectly by interfering with preg-
nancy development through its effects on decidual tissue.
Decidua is a proliferative, highly vascularized tissue derived
from stromal uterine cells during pregnancy that is abso-
lutely required for normal pregnancy development (31). The
possibility that blockage of the VEGF/VEGFR-2 pathway
might disrupt pregnancy development through interference
with uterine function was suggested by two recent studies (8,
9). We tested for such a possibility by following pregnancy
development in ovariectomized, P4-replaced animals ex-
posed to DC101 before and after implantation. P4 replace-
ment was able to completely reverse the effects of the
VEGFR-2-blocking antibody administered before or after im-
plantation of the embryo, and pregnancy continued to de-
velop normally. We conclude that the effects of the antibody
given to intact pregnant animals must have occurred spe-
cifically at the level of the ovary. Because pregnancy was able
to progress normally, potential effects of DC101 on decidual
tissue must have been insignificant. This conclusion is also
supported by the finding that the BVD of decidua was not
different between control and treatment groups. Therefore,
deciduas of mice seem to be more resistant to the antivascular
effects of anti-VEGFR-2 antibody DC101 compared with the
corpora lutea of pregnancy. Based on our findings, it is likely
that the disruption of pregnancy development through the
administration of anti-VEGF antibody, as reported by Rab-
bani and Rodgers (8) and Rockwell et al. (9), can be explained
by the effects of antibody on luteal function. Support for an
ovarian action of our antibody comes from studies in the
monkey, in which pregnancy continued to develop normally
in the presence of substances inactivating VEGF function,
which caused a temporary decrease in luteal P4 secretion
(27). A possible explanation might be that decidual endo-
thelial cells behave differently when exposed to the antibody
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compared with luteal endothelial cells, through a difference
in either the endowment of VEGFR-2 or associated down-
stream signaling molecules. In contrast, we cannot rule out
that administration of antibody at a higher dosage, initiation
of treatment before d 3.5, and/or administration over a
longer period of time could have affected decidual vascula-
ture and function significantly and, as a secondary effect,
could disrupt pregnancy development.
It is informative to compare the effects of DC101, an an-
tiangiogenic and antisurvival agent, with those of a sub-
stance that only blocks angiogenesis. An antibody developed
against VE-cadherin, E4G10, has such a profile (17). Both
antibodies inhibit angiogenesis during the formation of cor-
pora lutea. In contrast to DC101, luteal function during preg-
nancy was not affected by E4G10. When administered to
pregnant animals, the histological appearance of corpora
lutea, BVD, and serum P4 measurements were similar to
those in controls. These observations indicate that E4G10 did
not interfere with luteal endothelial cell survival and confirm
that blood vessel proliferation is not important for the func-
tion of corpora lutea during pregnancy (31).
Antibody DC101 shows strong antiangiogenic and an-
tisurvival properties in dynamic structures with high vas-
cular activity, such as corpora lutea, whereas it appears to
be innocuous to mature vasculature in permanent organs,
such as kidney, at least when administered short term.
Therefore, blockage of the VEGF/VEGFR-2 pathway with
DC101 has the potential for several applications in obstet-
rics and gynecology. New contraceptive strategies could
focus on the development of agents that disrupt ovarian
blood vessel function through blocking the VEGF/
VEGFR-2 pathway. The ability of the antibody to inhibit
pregnancy development in the preimplantation period
suggests that this knowledge could be used to control
fertility by developing another effective emergency morn-
ing-after alternative that might have fewer side-effects.
Furthermore, the antibody’s ability to disrupt pregnancy
development in the postimplantation period indicates that
it also has the potential to be used alone or in combination
with drugs such as prostaglandins or antiprogestins to
terminate abnormal intrauterine pregnancies as well as for
the treatment of ectopic pregnancies. These treatment pos-
sibilities have to be tested in a nonhuman primate model,
because the effects of interference with the VEGF/
VEGFR-2 pathway on pregnancy might vary in different
species (27).
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